Morphine promotes neovascularizing retinopathy in sickle transgeneic mice

Research output: Contribution to journalArticle

Abstract

Neovascularizing retinopathy is a significant complication of sickle cell disease (SCD), occurring more frequently in HbSC than HbSS disease. This risk difference is concordant with a divergence of angiogenesis risk, as identified by levels of pro- vs anti-angiogenic factors in the sickle patient’s blood. Because our prior studies documented that morphine promotes angiogenesis in both malignancy and wound healing, we tested whether chronic opioid treatment would promote retinopathy in NY1DD sickle transgenic mice. After 10 to 15 months of treatment, sickle mice treated with morphine developed neovascularizing retinopathy to a far greater extent than either of the controls (sickle mice treated with saline and wild-type mice treated identically with morphine). Our dissection of the mechanistic linkage between morphine and retinopathy revealed a complex interplay among morphine engagement with its m opioid receptor (MOR) on retinal endothelial cells (RECs); morphine-induced production of tumor necrosis factor a and interleukin-6 (IL-6), causing increased expression of both MOR and vascular endothelial growth factor receptor 2 (VEGFR2) on RECs; morphine/MOR engagement transactivating VEGFR2; and convergence of MOR, VEGFR2, and IL-6 activation on JAK/STAT3-dependent REC proliferation and angiogenesis. In the NY1DD mice, the result was increased angiogenesis, seen as neovascularizing retinopathy, similar to the retinal pathology occurring in humans with SCD. Therefore, we conclude that chronic opioid exposure, superimposed on the already angiogenic sickle milieu, might enhance risk for retinopathy. These results provide an additional reason for development and application of opioid alternatives for pain control in SCD.

Original languageEnglish (US)
Pages (from-to)1073-1083
Number of pages11
JournalBlood Advances
Volume3
Issue number7
DOIs
StatePublished - Apr 9 2019

Fingerprint

Morphine
Transgenic Mice
Opioid Receptors
Vascular Endothelial Growth Factor Receptor-2
Sickle Cell Anemia
Opioid Analgesics
Endothelial Cells
Interleukin-6
Angiogenesis Inducing Agents
Wound Healing
Dissection
Tumor Necrosis Factor-alpha
Cell Proliferation
Pathology
Pain
Therapeutics
Neoplasms

Cite this

Morphine promotes neovascularizing retinopathy in sickle transgeneic mice. / Gupta, Kalpna; Chen, Chunsheng; Lutty, Gerard A.; Hebbel, Robert P.

In: Blood Advances, Vol. 3, No. 7, 09.04.2019, p. 1073-1083.

Research output: Contribution to journalArticle

@article{1ea7004b7f1446f298438c1495a8c1b3,
title = "Morphine promotes neovascularizing retinopathy in sickle transgeneic mice",
abstract = "Neovascularizing retinopathy is a significant complication of sickle cell disease (SCD), occurring more frequently in HbSC than HbSS disease. This risk difference is concordant with a divergence of angiogenesis risk, as identified by levels of pro- vs anti-angiogenic factors in the sickle patient’s blood. Because our prior studies documented that morphine promotes angiogenesis in both malignancy and wound healing, we tested whether chronic opioid treatment would promote retinopathy in NY1DD sickle transgenic mice. After 10 to 15 months of treatment, sickle mice treated with morphine developed neovascularizing retinopathy to a far greater extent than either of the controls (sickle mice treated with saline and wild-type mice treated identically with morphine). Our dissection of the mechanistic linkage between morphine and retinopathy revealed a complex interplay among morphine engagement with its m opioid receptor (MOR) on retinal endothelial cells (RECs); morphine-induced production of tumor necrosis factor a and interleukin-6 (IL-6), causing increased expression of both MOR and vascular endothelial growth factor receptor 2 (VEGFR2) on RECs; morphine/MOR engagement transactivating VEGFR2; and convergence of MOR, VEGFR2, and IL-6 activation on JAK/STAT3-dependent REC proliferation and angiogenesis. In the NY1DD mice, the result was increased angiogenesis, seen as neovascularizing retinopathy, similar to the retinal pathology occurring in humans with SCD. Therefore, we conclude that chronic opioid exposure, superimposed on the already angiogenic sickle milieu, might enhance risk for retinopathy. These results provide an additional reason for development and application of opioid alternatives for pain control in SCD.",
author = "Kalpna Gupta and Chunsheng Chen and Lutty, {Gerard A.} and Hebbel, {Robert P.}",
year = "2019",
month = "4",
day = "9",
doi = "10.1182/bloodadvances.2018026898",
language = "English (US)",
volume = "3",
pages = "1073--1083",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - Morphine promotes neovascularizing retinopathy in sickle transgeneic mice

AU - Gupta, Kalpna

AU - Chen, Chunsheng

AU - Lutty, Gerard A.

AU - Hebbel, Robert P.

PY - 2019/4/9

Y1 - 2019/4/9

N2 - Neovascularizing retinopathy is a significant complication of sickle cell disease (SCD), occurring more frequently in HbSC than HbSS disease. This risk difference is concordant with a divergence of angiogenesis risk, as identified by levels of pro- vs anti-angiogenic factors in the sickle patient’s blood. Because our prior studies documented that morphine promotes angiogenesis in both malignancy and wound healing, we tested whether chronic opioid treatment would promote retinopathy in NY1DD sickle transgenic mice. After 10 to 15 months of treatment, sickle mice treated with morphine developed neovascularizing retinopathy to a far greater extent than either of the controls (sickle mice treated with saline and wild-type mice treated identically with morphine). Our dissection of the mechanistic linkage between morphine and retinopathy revealed a complex interplay among morphine engagement with its m opioid receptor (MOR) on retinal endothelial cells (RECs); morphine-induced production of tumor necrosis factor a and interleukin-6 (IL-6), causing increased expression of both MOR and vascular endothelial growth factor receptor 2 (VEGFR2) on RECs; morphine/MOR engagement transactivating VEGFR2; and convergence of MOR, VEGFR2, and IL-6 activation on JAK/STAT3-dependent REC proliferation and angiogenesis. In the NY1DD mice, the result was increased angiogenesis, seen as neovascularizing retinopathy, similar to the retinal pathology occurring in humans with SCD. Therefore, we conclude that chronic opioid exposure, superimposed on the already angiogenic sickle milieu, might enhance risk for retinopathy. These results provide an additional reason for development and application of opioid alternatives for pain control in SCD.

AB - Neovascularizing retinopathy is a significant complication of sickle cell disease (SCD), occurring more frequently in HbSC than HbSS disease. This risk difference is concordant with a divergence of angiogenesis risk, as identified by levels of pro- vs anti-angiogenic factors in the sickle patient’s blood. Because our prior studies documented that morphine promotes angiogenesis in both malignancy and wound healing, we tested whether chronic opioid treatment would promote retinopathy in NY1DD sickle transgenic mice. After 10 to 15 months of treatment, sickle mice treated with morphine developed neovascularizing retinopathy to a far greater extent than either of the controls (sickle mice treated with saline and wild-type mice treated identically with morphine). Our dissection of the mechanistic linkage between morphine and retinopathy revealed a complex interplay among morphine engagement with its m opioid receptor (MOR) on retinal endothelial cells (RECs); morphine-induced production of tumor necrosis factor a and interleukin-6 (IL-6), causing increased expression of both MOR and vascular endothelial growth factor receptor 2 (VEGFR2) on RECs; morphine/MOR engagement transactivating VEGFR2; and convergence of MOR, VEGFR2, and IL-6 activation on JAK/STAT3-dependent REC proliferation and angiogenesis. In the NY1DD mice, the result was increased angiogenesis, seen as neovascularizing retinopathy, similar to the retinal pathology occurring in humans with SCD. Therefore, we conclude that chronic opioid exposure, superimposed on the already angiogenic sickle milieu, might enhance risk for retinopathy. These results provide an additional reason for development and application of opioid alternatives for pain control in SCD.

UR - http://www.scopus.com/inward/record.url?scp=85068307180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068307180&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2018026898

DO - 10.1182/bloodadvances.2018026898

M3 - Article

C2 - 30944099

AN - SCOPUS:85068307180

VL - 3

SP - 1073

EP - 1083

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 7

ER -